



Scientific Basis for Comprehensive In vitro Proarrhythmia Assay

John Koerner, Ph.D.
DCRP/FDA


HESI/CSRC July 23, 2013



Disclaimer

The thoughts expressed here are
those of the speaker and do not
necessarily reflect those of the FDA.

Cardiac Ionic Currents



Cardiac Channel Panel™	AP Phase
Nav1.5 (I_{Na})	0, 2
Cav1.2/ β , α , δ , (L-type)	2
Cav3.2 (T-type)	1
Kv4.3 (I_{To1})	1
KvLQT1/minK (I_{Kr})	2 - 3
hERG (I_{Kc})	2 - 3
Kv1.5 (I_{Kur})	2 - 3
Kir2.1 (I_{K1})	4
HCN2 (pacemaker, I_h)	4
HCN4 (pacemaker, I_h)	4
Kir3.1/3.4 ($I_{K,ACh}$)	4
Kir6.2/SUR2A ($I_{K,ATP}$)	4
NCX1 (Na-Ca exchange)	2

Why hERG?

- Major repolarizing current
- Inhibition responsible for TdP
 - Terfenadine
 - Cisapride
 - Bepridil
 - etc



Evolution of thinking - hERG

- Blockade is bad - any dose/concentration
- Potency needs to be considered
- Potency relative to therapeutic concentration considered

5



Multiple Ion Channel Inhibitors

- Consider both outward, e.g., hERG
- And inward currents, I_{Ca}, I_{Na}

6

Multichannel Inhibitors

Proarrhythmic

- Quinidine
- Terfenadine
- Bepridil
- Terodiline

Benign

- Verapamil
- Ranolazine
- Tolterodine

7

MICE Models: Superior to the HERG Model in Predicting Torsade de Pointes

James Kramer^{1*}, Carlos A. Obejero-Paz^{1*}, Glenn Myatt², Yuri A. Kuryshv¹, Andrew Bruening-Wright¹, Joseph S. Verducci³ & Arthur M. Brown¹

¹ChanTest Corporation, 14656 Neo Parkway, Cleveland, OH 44128, ²Leadscope, Inc., 1393 Dublin Rd, Columbus, Ohio 43215, ³The Ohio State University, 440 N Cockins Hall, 1958 Neil Ave., Columbus, OH 43210.

Drug-induced block of the cardiac hERG (human Ether-à-go-go-Related Gene) potassium channel delays cardiac repolarization and increases the risk of Torsade de Pointes (TdP), a potentially lethal arrhythmia. A positive hERG assay has been embraced by regulators as a non-clinical predictor of TdP despite a discordance of about 30%. To test whether assaying concomitant block of multiple ion channels (Multiple Ion Channel Effects or MICE) improves predictivity we measured the concentration-responses of hERG, Nav1.5 and Cav1.2 currents for 32 torsadogenic and 23 non-torsadogenic drugs from multiple classes. We used automated gigaseal patch clamp instruments to provide higher throughput along with accuracy and reproducibility. Logistic regression models using the MICE assay showed a significant reduction in false positives (Type 1 errors) and false negatives (Type 2 errors) when compared to the hERG assay. The best MICE model only required a comparison of the blocking potencies between hERG and Cav1.2.

8

hERG, ICa, INa






Figure 1 | IC_{50} s of the 55 drugs included in the dataset for hERG, Cav1.2 and Nav1.5. Symbols indicate mean values and lines the 95% confidence intervals of data. Values for the three channels are plotted as a function of drugs numbered in decreased order of potency. The drug order for each channel is indicated in [Supplementary Table 3](#).





C Model 1 (0.77 ± 0.07)

	+TdP	-TdP
Correctly classified	26	15
Incorrectly classified	6	8

False Positives
ceftriaxone
linezolid
metronidazole
phenytoin
piperacillin
ribavirin
telbivudine
verapamil

False Negatives
amiodarone
clostazol
paroxetine
risperidone
solifenacin
sunitinib

Model 5 (0.93 ± 0.04)

	+TdP	-TdP
Correctly classified	31	19
Incorrectly classified	1	4

False Positives
dasatinib
donepezil
loratadine
telbivudine

False Negatives
voriconazole

Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk

Gary R. Mirams^{1*}, Yi Cui², Anna Sher¹, Martin Fink¹, Jonathan Cooper³,
Bronagh M. Heath⁴, Nick C. McMahon², David J. Gavaghan³, and Denis Noble¹

¹Department of Physiology, Anatomy and Genetics, University of Oxford, Sherrington Building, Parks Road, Oxford, OX1 3PT, UK; ²Safety Pharmacology, Safety Assessment, GlaxoSmithKline, Ware SG12 0DP, UK; ³Computing Laboratory, University of Oxford, Parks Road, Oxford OX1 3QD, UK; and ⁴Global Clinical Safety and Pharmacovigilance, GlaxoSmithKline, Uxbridge UB11 1BT, UK

Received 4 January 2011; revised 31 January 2011; accepted 3 February 2011; online publish-ahead-of-print 7 February 2011

Time for primary review: 19 days


Aims The level of inhibition of the human Ether-à-go-go-related gene (hERG) channel is one of the earliest preclinical markers used to predict the risk of a compound causing Torsade-de-Pointes (TdP) arrhythmias. While avoiding the use of drugs with maximum therapeutic concentrations within 30-fold of their hERG inhibitory concentration 50% (IC₅₀) values has been suggested, there are drugs that are exceptions to this rule: hERG inhibitors that do not cause TdP, and drugs that can cause TdP but are not strong hERG inhibitors. In this study, we investigate whether a simulated evaluation of multi-channel effects could be used to improve this early prediction of TdP risk.

Methods and results We collected multiple ion channel data (hERG, Na, L-type Ca) on 31 drugs associated with varied risks of TdP. To integrate the information on multi-channel block, we have performed simulations with a variety of mathematical models of cardiac cells (for rabbit, dog, and human ventricular myocyte models). Drug action is modelled using IC₅₀ values, and therapeutic drug concentrations to calculate the proportion of blocked channels and the channel conductances are modified accordingly. Various pacing protocols are simulated, and classification analysis is performed to evaluate the predictive power of the models for TdP risk. We find that simulation of action potential duration prolongation, at therapeutic concentrations, provides improved prediction of the TdP risk associated with a compound, above that provided by existing markers.

Conclusion The suggested calculations improve the reliability of early cardiac safety assessments, beyond those based solely on a hERG block effect.

Keywords Computer modelling • Drug development • Pharmacology • Risk prediction • Torsade-de-pointes

hERG vs Reconstructed APD



13

Comprehensive In vitro Proarrhythmia Assay (CIPA)

- Continuation of evolution
- More comprehensive than hERG alone
- Targeted towards prediction of proarrhythmic potential
- Available data supports the concept

14



Thank you